Migraine Cephalalgia
Find information on Migraine Cephalalgia diagnosis, including ICD-10 code G43.1, clinical documentation requirements, headache symptoms, and treatment options. Learn about migraine diagnosis criteria, differential diagnosis considerations, and best practices for healthcare professionals documenting migraine in medical records. Explore resources for accurate medical coding and billing related to migraine cephalalgia.
Severe, recurring headache often accompanied by nausea, vomiting, and sensitivity to light and sound.
Pulsating, unilateral head pain, nausea, vomiting, photophobia, phonophobia, aura (visual disturbances).
Neurology clinic, primary care, urgent care, telehealth.
ICD-10 Code Families
Complete code families applicable to G43.909
When to use each related code
| Description | When to use |
|---|---|
| Migraine headache | Use for throbbing, often one-sided headache with nausea, light sensitivity. Consider aura, triggers. |
| Tension-type headache | Use for mild to moderate, bilateral head pain described as tight band or pressure. Usually no nausea. |
| Cluster headache | Use for severe, unilateral orbital, supraorbital or temporal pain with autonomic symptoms. Episodic attacks. |
Best-practice checklist
- ✓Migraine diagnosis: Document headache characteristics (location, quality, severity)
- ✓Migraine documentation: Include associated symptoms (nausea, photophobia, phonophobia)
- ✓Migraine coding: Specify with or without aura (ICHD-3 criteria)
- ✓Migraine record: Number and duration of attacks
- ✓Migraine notes: Document impact on daily activities and response to treatment
Best-practice tips
- 01Document migraine triggers (e.g., stress, caffeine) for accurate ICD-10 coding (G43.x).
- 02Ensure consistent CDI of migraine subtypes (with/without aura) for proper billing.
- 03Track migraine frequency and severity in patient records for compliance and trending.
- 04Educate patients on preventative strategies (lifestyle, medication) to reduce healthcare utilization.
- 05Review medical necessity for imaging studies per payer guidelines to minimize denials (G43).
Step-by-step checklist
- 1
Unilateral pulsating head pain? Documented?
- 2
Moderate or severe pain intensity? Documented?
- 3
Nausea or vomiting OR photophobia AND phonophobia? Documented?
- 4
Symptoms last 4-72 hours untreated? Documented?
- 5
Not better accounted for by another ICHD-3 diagnosis? Documented?
Ready-to-paste narrative
Patient presents with a complaint of migraine headache, characterized by severe, throbbing, unilateral head pain. The patient reports a history of migraine with aura, describing visual disturbances such as scintillating scotoma preceding the headache onset. Associated symptoms include photophobia, phonophobia, and nausea. The patient denies vomiting, fever, or neck stiffness. Pain is exacerbated by routine physical activity and relieved by rest and darkness. Family history is positive for migraine headaches. Neurological examination is unremarkable. Diagnosis of migraine cephalalgia (ICD-10 G43.1, migraine with aura; or G43.90, migraine unspecified, if aura is absent) is made based on patient history, symptom presentation, and absence of other neurological findings. Differential diagnoses considered include tension-type headache, cluster headache, and secondary headache disorders. Treatment plan includes administration of sumatriptan succinate for acute migraine relief and patient education on migraine triggers, preventative measures, and lifestyle modifications. Patient advised to maintain a headache diary to track frequency, severity, and duration of migraine attacks. Follow-up appointment scheduled to assess treatment efficacy and discuss potential prophylactic medication options if needed, such as topiramate or propranolol. Patient counseled on the importance of medication adherence and potential side effects.
Common questions and answers
How can I differentiate between migraine with aura and transient ischemic attack (TIA) in a clinical setting to ensure accurate diagnosis and avoid misdiagnosis?+
Differentiating between migraine with aura and TIA can be challenging due to overlapping symptoms. Focus on key distinctions. TIA symptoms tend to be negative (e.g., numbness, weakness) and resolve quickly, usually within an hour, without the typical headache phase of migraine. Migraine aura, while also often visual, tends to develop more gradually (over minutes) and involve positive phenomena (e.g., scintillations, fortification spectra). Headache usually follows, though it can sometimes be delayed or absent. Thorough neurological examination, including assessment of visual fields and cranial nerves, is crucial. Consider neuroimaging (MRI or CT) if symptoms are atypical, onset is abrupt, or neurological deficits persist. A detailed patient history, including age, vascular risk factors, and prior migraine history, is essential. Explore how risk stratification tools can aid in differentiating these conditions. Learn more about specific aura characteristics that can help distinguish migraine from TIA.
What are the evidence-based non-pharmacological treatment options for migraine management in adults, especially for patients who prefer avoiding medications or have contraindications to specific drugs?+
Non-pharmacological treatments play an important role in migraine management, offering alternatives for patients unable or unwilling to use medication. Evidence supports several approaches. Cognitive behavioral therapy (CBT) and biofeedback have demonstrated efficacy in reducing migraine frequency and intensity. Mindfulness-based stress reduction and relaxation techniques can also be beneficial. Lifestyle modifications, including regular sleep, a balanced diet, and identification and avoidance of triggers (e.g., certain foods, stress), are often recommended as first-line interventions. Aerobic exercise, such as brisk walking or cycling, can also help reduce migraine burden. Consider implementing a comprehensive, multidisciplinary approach that combines these non-pharmacological options. Explore how patient education and self-management strategies can empower individuals to control their migraines effectively.
What are the current best practice guidelines for prescribing prophylactic medication for migraine, considering factors like patient comorbidities, potential drug interactions, and cost-effectiveness?+
Prophylactic migraine medication is indicated for patients with frequent or severe migraines that significantly impact quality of life and are inadequately controlled by acute treatments. Choice of prophylactic medication should consider individual patient factors, including comorbidities, potential drug interactions, and cost-effectiveness. Beta-blockers (e.g., metoprolol, propranolol), antidepressants (e.g., amitriptyline, venlafaxine), anticonvulsants (e.g., topiramate, valproate), and CGRP monoclonal antibodies are commonly used. Patient preference and potential side effects also influence medication choice. Start with a low dose and titrate upwards as tolerated, carefully monitoring for adverse effects. Regular follow-up is crucial to assess efficacy and adjust treatment as needed. Learn more about the latest AHS/AAN guidelines for migraine prevention and consider implementing shared decision-making in choosing the most appropriate prophylactic therapy.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.